Bristol-Myers Squibb's psoriasis and psoriatic arthritis treatment drug Sotyktu approved by the FDA

TechubNews · 2026-03-07T18:20:32+00:00

Bristol-Myers Squibb announces that its drug Sotyktu has received FDA approval for the treatment of adult active psoriatic arthritis. Studies show that the effective response rate for the 6mg dose is significantly higher than the placebo group. Common adverse reactions include upper respiratory tract infections, and caution should be exercised regarding the risks of infections and malignancies.

TechubNews

2026-03-07 18:20:32

Abstract generation in progress

Bristol-Myers Squibb announced on March 7, 2026, that Sotyktu (deucravacitinib) has received FDA approval for the treatment of adult active psoriatic arthritis. This approval is supported by key POETYK PsA-1 and PsA-2 studies, which showed that patients taking 6 mg of Sotyktu once daily achieved a 54% response rate at week 16 based on ACR20 criteria in PsA-1, 34% higher than the placebo group; similarly, in PsA-2, the response rate was 54%, 39% higher than placebo. Common adverse reactions of Sotyktu include upper respiratory tract infections, elevated creatine phosphokinase, herpes simplex, mouth ulcers, folliculitis, and acne. Additionally, warnings include infections, malignancies including lymphoma, rhabdomyolysis, laboratory abnormalities, and potential risks associated with JAK inhibition.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.